# Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

> **NCT05400265** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 9 (actual)

## Conditions studied

- Adult Solid Tumor

## Interventions

- **DRUG:** HLX26
- **DRUG:** HLX10

## Key facts

- **NCT ID:** NCT05400265
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-26
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400265, "Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05400265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*